Loading…
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $510M | $198M | $147M | $28M | 30.8% | 19.6% | -25.7% |
| 2024 | $426M | $148M | $198M | $110M | 56.6% | 65.2% | -800.0% |
| 2023 | $258M | $5M | $-28M | $4M | -20.9% | 67.6% | -57.2% |
| 2022 | $154M | $-40M | $-66M | $-73M | -43.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 154.08 | 258.21 | 426.45 | 510.17 |
| Cost Of Revenue | - | 118.82 | 169.27 | 206.90 | 217.41 |
| Gross Profit | - | 35.26 | 88.94 | 219.55 | 292.76 |
| Operating Expense | - | 74.63 | 67.31 | 80.57 | 101.32 |
| Operating Income | - | -39.36 | 21.63 | 138.98 | 191.44 |
| EBITDA | - | -39.51 | 5.12 | 147.69 | 197.86 |
| EBIT | - | -46.62 | -3.21 | 139.64 | 189.77 |
| Pretax Income | - | -65.90 | -28.24 | 125.71 | 182.66 |
| Tax Provision | - | 0 | 0 | -71.96 | 35.73 |
| Net Income | - | -65.90 | -28.24 | 197.67 | 146.93 |
| Net Income Common Stockholders | - | -65.90 | -28.24 | 197.67 | 146.93 |
| Total Expenses | - | 193.44 | 236.58 | 287.47 | 318.73 |
| Interest Expense | - | 19.28 | 25.03 | 13.93 | 7.11 |
| Interest Income | - | 0.04 | 1.62 | 2.10 | 1.87 |
| Research And Development | - | 3.61 | 3.30 | 1.81 | 4.76 |
| Selling General And Administration | - | 52.46 | 59.02 | 74.12 | 91.58 |
| Normalized EBITDA | - | -32.84 | 31.29 | 148.93 | 201.20 |
| Normalized Income | - | -59.23 | -2.06 | 198.65 | 149.61 |
| Market Cap | 2,615.97 | 2,615.97 | 2,615.97 | 2,615.97 | 2,615.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ADMA Biologics, Inc.this co. | ADMA | - | 17.80↓ discount | 5.48 | 30.8% | 13.18 |
| Integer Holdings Corporation | ITGR | $3.0B | 28.79 | 1.69 | 5.9% | 14.55 |
| Organon & Co. | OGN | $2.9B | 15.67 | 3.90 | 24.9% | 8.53 |
| Prestige Consumer Healthcare Inc. | PBH | $2.9B | 13.00 | 1.52 | 11.7% | 10.32 |
| Privia Health Group, Inc. | PRVA | $2.9B |
| - |
| - |
| - |
| - |
| - |
| 130.67 |
| 4.06 |
| 3.1% |
| 57.20 |
| Veracyte, Inc. | VCYT | $2.7B | 41.28 | 2.09 | 5.1% | 26.96 |
| National HealthCare Corporation | NHC | $2.7B | 22.47 | 2.52 | 11.2% | 12.59 |
| LeMaitre Vascular, Inc. | LMAT | $2.6B | 44.90 | 6.59 | 14.7% | 30.28 |
| Phibro Animal Health Corporation | PAHC | $2.2B | 46.33 | 7.83 | 16.9% | 19.95 |
| Peer Median | - | 35.04 | 3.21 | 11.5% | 17.25 | |